Korea Q3 Roundup: Mixed Results Amid Focus On Obesity, New Drugs
Hanmi Set For Record Year
As Korean firms report quarterly earnings, Hanmi is stepping up the development of obesity drugs, Daewoong unveils plans to boost sales of in-house new drugs, GC Biopharma’s immunoglobulin undergoes the US approval process and Ildong has set up a new R&D-focused subsidiary.
You may also be interested in...
At the recent World Bio Summit in Seoul, global health leaders discussed international cooperation strategies and policies to prepare for the next pandemic, with a focus on rapid vaccine development.
Recent sizable out-licensing deals with global big pharma firms are raising hopes of a recovery in Korean biopharma alliances and also point to possible changes in deal structures towards international norms.
Plus deals involving Fujimoto/Egetis, Chugai/Cheplapharm, Celest/Senti, Shionogi/Apnimed, Jiangsu Hengrui/Merck KGaA, Jiangsu Hengrui/Elevar, Sun/Zydus, C4U/Healiva, Shanghai Henlius/Intas, Ono/Turbine, EpimAB/Almirall and Alar/Indivior.